Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14160339 | 0.84 | SLC22A12 (0.68) | SLC22A12MCL1ACLY | |
| SCHEMBL2740996 | 0.78 | PTGES2 (0.56) | MCL1PTGES2FBP1 | |
| SCHEMBL31314298 | 0.78 | SLC22A12 (0.54) | SLC22A12ACLYPTGES2 | |
| SCHEMBL28750138 | 0.77 | SLC22A12 (0.63) | SLC22A12MCL1 | |
| SCHEMBL2740981 | 0.77 | PTGES2 (0.58) | MCL1PTGES2 | |
| SCHEMBL27761878 | 0.74 | SLC22A12 (0.58) | SLC22A12MCL1ACLY | |
| SCHEMBL2740980 | 0.73 | KDM4E (0.54) | ACLY | |
| SCHEMBL2740977 | 0.73 | KLK7 (0.48) | MCL1PTGES2 | |
| SCHEMBL31314437 | 0.73 | SLC22A12 (0.54) | SLC22A12ACLYPTGES2 | |
| SCHEMBL7596336 | 0.73 | HSD11B1 (0.55) | SLC22A12PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088772-B2 | Sulfonamides and their use as a medicament | THE GENETICS COMPANY, INC. (CH) | 2012-01-03 | — | — | US | disclosed |
| US-8088772-B2 | Sulfonamides and their use as a medicament | THE GENETICS COMPANY, INC. (CH) | 2012-01-03 | — | — | US | disclosed |
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | BCOR, CBR3, SULT1E1 | SLC22A12 1314/4885MCL1 602/4885ACLY 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.